Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Activity Highlights Interest In Bispecific Antibodies

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bispecific antibodies can be developed using many different formats for multiple therapeutic areas (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)). Big pharmas have inked deals with modest upfront payments to explore the use of a variety of technology applications.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel